Yuhan Corporation, Q2 Operating Profit Surges by 190%... 'Leclaza' Effect

[Financial News] Yuhan Corporation recorded remarkable growth in its Q2 performance, driven by the technology transfer revenue of the lung cancer treatment 'Leclaza (ingredient name: Lazertinib)'. On the 30th, Yuhan Corporation announced through a provisional performance disclosure that its Q2 operating profit increased by 190.1% year-on-year to 45.6 billion won. During the same period, sales increased by 8.1% year-on-year to 556.2 billion won.
The biggest factor behind this strong performance is the surge in technology fee revenue. Yuhan Corporation announced that it is scheduled to receive milestone revenue of approximately 20.7 billion won from the global pharmaceutical company Janssen in relation to the commercialization of the lung cancer treatment Leclaza in Japan.
Accordingly, technology fee revenue was tallied at 25.5 billion won, more than 4500% year-on-year.
The overseas business segment also maintained a solid trend. Q2 overseas sales increased by 18.1% year-on-year to 114.8 billion won. However, there was some disparity in the domestic pharmaceutical market.
The over-the-counter (OTC) segment recorded 57.4 billion won, a 9.7% increase year-on-year, while the prescription drug (ETC) segment, affected by recent collective actions in the medical community, only increased by 0.3% year-on-year.
The cumulative performance in the first half of this year also continues a positive trend. Cumulative sales in the first half increased by 8.2% year-on-year to 1.0256 trillion won, and operating profit increased by 148.1% to 54.3 billion won.

vrdw88@fnnews.com Kang Jung-mo Reporter